ArticleLupus science & medicine2015
BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year.
Article in Lupus science & medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 51 citations in OpenAlex.
- The role of baseline BLyS levels and type 1 interferon-inducible gene signature status in determining belimumab response in systemic lupus erythematosus: a post hoc meta-analysis.Arthritis research & therapy · 2020Pooled it
- Development of a Time-Resolved Fluorescence Immunoassay for BAFF and Its Preliminary Clinical Application in Patients with Lupus Nephritis.Journal of fluorescence · 2026Article
- Redefining Difficult-to-Treat Systemic Lupus Erythematosus: Biomarkers of Molecular Refractoriness Beyond Clinical Failure.International journal of molecular sciences · 2026Review
- Anti-TFAM antibodies link mitochondrial damage with antiphospholipid syndrome and thrombosis in SLE.Annals of the rheumatic diseases · 2025Article
- Advances in Targeted Therapy for Systemic Lupus Erythematosus: Current Treatments and Novel Approaches.International journal of molecular sciences · 2025Review
- Effectiveness and safety of Belimumab and Telitacicept in systemic lupus erythematosus: a real-world, retrospective, observational study.Clinical rheumatology · 2025Observational
- Role of ncRNAs in the Pathogenesis of Sjögren's Syndrome.Biomedicines · 2024Review
- Uncoupling interferons and the interferon signature explains clinical and transcriptional subsets in SLE.Cell reports. Medicine · 2024Article
- Immunotherapy Strategy for Systemic Autoimmune Diseases: Betting on CAR-T Cells and Antibodies.Antibodies (Basel, Switzerland) · 2024Review
- B Cell Tolerance and Targeted Therapies in SLE.Journal of clinical medicine · 2023Review
- Uncoupling interferons and the interferon signature explain clinical and transcriptional subsets in SLE.medRxiv : the preprint server for health sciences · 2023Article
- Differential expression of IFN-α, IL-12 and BAFF on renal immune cells and its relevance to disease activity and treatment responsiveness in patients with proliferative lupus nephritis.Lupus science & medicine · 2023Article
- Precision medicine in systemic lupus erythematosus.Nature reviews. Rheumatology · 2023Review
- Affinity maturation generates pathogenic antibodies with dual reactivity to DNase1L3 and dsDNA in systemic lupus erythematosus.Nature communications · 2023Article
- B cell-activating factor (BAFF) from dendritic cells, monocytes and neutrophils is required for B cell maturation and autoantibody production in SLE-like autoimmune disease.Frontiers in immunology · 2023Article
- Alternative exon usage in TRIM21 determines the antigenicity of Ro52/TRIM21 in systemic lupus erythematosus.JCI insight · 2022Article
- Autoantibodies targeting LINE-1-encoded ORF1p are associated with systemic lupus erythematosus diagnosis but not disease activity.Clinical and experimental rheumatology · 2022Article
- Role of the innate and adaptive immune responses in the pathogenesis of systemic lupus erythematosus.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2022Review
- Soluble markers of B cell activation suggest a role of B cells in the pathogenesis of systemic sclerosis-associated pulmonary arterial hypertension.Frontiers in immunology · 2022Article
- New biomarkers in SLE: from bench to bedside.Rheumatology (Oxford, England) · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 1 country.
Funding
Abstract
objectivesQuantitating gene expression is a potential method of developing biomarkers in systemic lupus erythematosus (SLE). Because of the known pathological role of B cell activating factor (BAFF) in SLE, we explored the association between BAFF gene expression and clinical activity in SLE.
methodsA total of 275 patients with SLE completed this phase of a prospective observational study. At entry into the study, the BAFF gene expression levels were determined in peripheral blood RNA. Serum concentration of BAFF protein was also measured. We then determined clinical associations with SLE disease history, SLE activity on the same day and SLE activity over the course of the next year.
resultsElevated BAFF gene expression was associated with a history of more leucopenia and serologically with more autoantibodies (anti-dsDNA, anti-Sm, anti-Ro, anti-La and anti-RNP) and low complement. Patients with higher amounts of BAFF transcript had higher measured levels of clinical disease activity. Initial high levels of BAFF gene expression also predicted increased disease activity over the course of the next year. In contrast, serum concentration of BAFF protein was not strongly associated with same-day global disease activity or with future disease activity.
conclusionsBAFF gene expression level is associated with clinical and serological SLE activity on the same day and predictive of clinical activity over the next year. BAFF gene expression is a better measure and predictor of SLE disease activity than the serum BAFF protein level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.